AxoGen (NASDAQ:AXGN) Stock Price Down 4.3% - Should You Sell?

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report)'s share price traded down 4.3% during mid-day trading on Thursday . The company traded as low as $13.66 and last traded at $13.84. 50,139 shares were traded during mid-day trading, a decline of 87% from the average session volume of 399,537 shares. The stock had previously closed at $14.46.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $15.00 price target on shares of AxoGen in a research note on Thursday, June 20th. JMP Securities boosted their price target on shares of AxoGen from $17.00 to $20.00 and gave the company a "market outperform" rating in a research note on Friday, August 9th. StockNews.com raised shares of AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday. Finally, Raymond James began coverage on shares of AxoGen in a research note on Monday, July 1st. They set an "outperform" rating and a $13.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $15.00.

AxoGen Stock Performance

The stock's 50-day simple moving average is $13.26 and its 200 day simple moving average is $9.40. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.32 and a current ratio of 3.51. The company has a market capitalization of $578.65 million, a PE ratio of -26.48 and a beta of 1.13.

AxoGen (NASDAQ:AXGN - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. The company had revenue of $47.91 million for the quarter, compared to the consensus estimate of $43.27 million. As a group, research analysts expect that AxoGen, Inc. will post -0.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new position in shares of AxoGen in the 3rd quarter valued at $56,000. Creative Planning boosted its holdings in shares of AxoGen by 152.2% in the 3rd quarter. Creative Planning now owns 29,790 shares of the medical equipment provider's stock valued at $418,000 after buying an additional 17,980 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of AxoGen in the 3rd quarter valued at $227,000. Squarepoint Ops LLC boosted its holdings in shares of AxoGen by 186.1% in the 2nd quarter. Squarepoint Ops LLC now owns 60,913 shares of the medical equipment provider's stock valued at $441,000 after buying an additional 39,624 shares in the last quarter. Finally, First Light Asset Management LLC boosted its holdings in shares of AxoGen by 336.6% in the 2nd quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider's stock valued at $24,211,000 after buying an additional 2,578,147 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company's stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.